Erika Hamilton, MD, on T-DXd for Metastatic Breast Cancer: Clinical Considerations

Posted: Friday, July 8, 2022

Erika Hamilton, MD, of Sarah Cannon Research Institute at Tennessee Oncology, discusses phase III data from the DESTINY-Breast03 study, which reinforced the consistent safety profile of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive unresectable and/or metastatic breast cancer. Dr. Hamilton addresses nausea, alopecia, and pneumonitis, and offers clinical pearls on making treatment easier to tolerate.